Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis

  • Faranak Salajegheh (Clinical Research Development Unit, School of Medicine, Afzalipour Hospital, Kerman University of Medical Sciences) ;
  • Mohammad Rezaei Zadeh Rukerd (Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences) ;
  • Mohsen Nakhaie (Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences) ;
  • Zohreh-Al-Sadat Ghoreshi (School of Medicine, Jiroft University of Medical Sciences) ;
  • Javad Charostad (Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Science) ;
  • Nasir Arefinia (School of Medicine, Jiroft University of Medical Sciences)
  • Received : 2023.07.13
  • Accepted : 2023.12.26
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The emergence of coronavirus disease 2019 (COVID-19) vaccines has been a remarkable advancement. However, the efficacy, immunogenicity, and safety of these vaccines in individuals with liver cirrhosis require careful evaluation due to their compromised immune status and potential interactions with underlying liver disease. The present study aimed to evaluate the safety and efficacy of COVID-19 vaccines in liver cirrhosis patients. In the present study, we searched international databases, including Google Scholar, PubMed, Scopus, Embase, and Web of Science. The search strategy was carried out by using keywords and MeSH (Medical Subject Headings) terms. STATA ver. 15.0 (Stata Corp., USA) was used to analyze the data statistically. The analysis was performed using the randomeffects model. We also used the chi-square test and I2 index to calculate heterogeneity among studies. For evaluating publication bias, Begg's funnel plots and Egger's tests were used. A total of 4,831 liver cirrhosis patients with COVID-19 were examined from 11 studies. The rate of hospitalization in the patients with liver cirrhosis was 17.6% (95% confidence interval [CI], 9%-44%). The rate of fever in the patients with liver cirrhosis was 4.5% (95% CI, 0.9%-8.1%). The rate of positive neutralizing antibodies in the patients with liver cirrhosis was 82.5% (95% CI, 69.8%-95.1%). Also, the rates of seroconversion after the second vaccination in patients with liver cirrhosis and the control group were 96.6% (95% CI, 92.0%-99.0%), and 99.7% (95% CI, 99.0%-100.0%), respectively. COVID-19 vaccines have demonstrated promising efficacy, immunogenicity, and safety profiles in individuals with liver cirrhosis, providing crucial protection against COVID-19-related complications.

Keywords

References

  1. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ 2020;730:138996.
  2. Shafieipour S, Rezaei Zadeh Rukerd M, Shamsizadeh Meymandi T, et al. The effect of intravenous tocilizumab therapy on the prognosis of patients with COVID-19: a case-control study. Iran J Med Microbiol 2023;17:243-50.
  3. Haghpanah F, Lin G, Levin SA, Klein E. Analysis of the potential impact of durability, timing, and transmission blocking of COVID-19 vaccine on morbidity and mortality. EClinicalMedicine 2021;35:100863.
  4. Russell FM, Greenwood B. Who should be prioritised for COVID-19 vaccination? Hum Vaccin Immunother 2021;17:1317-21.
  5. Bottcher K, Pinzani M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv Drug Deliv Rev 2017;121:3-8.
  6. Ye F, Zhai M, Long J, et al. The burden of liver cirrhosis in mortality: results from the global burden of disease study. Front Public Health 2022;10:909455.
  7. Zahedi MJ, Shafieipour S, Hayatbakhsh Abbasi MM, et al. Mortality trends of gastrointestinal, liver, and pancreaticcobiliary diseases: a hospital-based prospective study in the southeast of Iran. Middle East J Dig Dis 2022;14:404-9.
  8. Cabibbo G, Rizzo GE, Stornello C, Craxi A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J Viral Hepat 2021;28:4-11.
  9. Khamees A, Bani-Issa J, Zoubi MS, et al. SARS-CoV-2 and coronavirus disease mitigation: treatment options, vaccinations and variants. Pathogens 2022;11:275.
  10. Shaik RA, Ahmad MS, Alzahrani M, et al. Comprehensive highlights of the universal efforts towards the development of COVID-19 vaccine. Vaccines (Basel) 2022;10:1689.
  11. Forni G, Mantovani A; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 2021;28:626-39.
  12. Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021;27:1693-5.
  13. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:1725-35.
  14. Ayenigbara IO, Adegboro JS, Ayenigbara GO, Adeleke OR, Olofintuyi OO. The challenges to a successful COVID-19 vaccination programme in Africa. Germs 2021;11:427-40.
  15. Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol 2021;74:944-51.
  16. Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol 2021;75:1434-9.
  17. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [Internet]. Burlington (MA): Science-Open; 2015 [cited 2023 May 18]. Available from: https://www.scienceopen.com/document?vid=54b48470-4655-4081-b5d4-e8ebe8d1792e
  18. Ivashkin V, Ismailova A, Dmitrieva K, et al. Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. World J Hepatol 2022;14:1470-9.
  19. Wang J, Zhang Q, Ai J, et al. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int 2022;16:691-701.
  20. Ruether DF, Schaub GM, Duengelhoef PM, et al. SARSCoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol 2022;20:162-72.
  21. Bakasis AD, Bitzogli K, Mouziouras D, et al. Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases. Viruses 2022;14:207.
  22. Goel A, Verma A, Tiwari P, et al. Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield(R)) in patients with liver cirrhosis. Vaccines (Basel) 2022;10:1837.
  23. Diaz LA, Fuentes-Lopez E, Lazo M, Kamath PS, Arrese M, Arab JP. Vaccination against COVID-19 decreases hospitalizations in patients with cirrhosis: results from a nationwide analysis. Liver Int 2022;42:942-4.
  24. Willuweit K, Frey A, Passenberg M, et al. Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers. Vaccines (Basel) 2022;10:377.
  25. Singh A, De A, Singh MP, et al. Antibody response and safety of ChAdOx1-nCOV (Covishield) in patients with cirrhosis: a cross-sectional, observational study. Dig Dis Sci 2023;68:676-84.
  26. Giambra V, Piazzolla AV, Cocomazzi G, et al. Effectiveness of booster dose of anti SARS-CoV-2 BNT162b2 in cirrhosis: longitudinal evaluation of humoral and cellular response. Vaccines (Basel) 2022;10:1281.
  27. Stroffolini T, Ciancio A, Federico A, et al. COVID-19 vaccination among cirrhotics in Italy: high coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization. Dig Liver Dis 2023;55:316-21.
  28. Iavarone M, Tosetti G, Facchetti F, et al. Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: a prospective single center study. Dig Liver Dis 2023;55:160-8.
  29. Geerling E, Hameed M, Weger-Lucarelli J, Pinto AK. Metabolic syndrome and aberrant immune responses to viral infection and vaccination: Insights from small animal models. Front Immunol 2022;13:1015563.
  30. Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021;19:173.
  31. Cao Z, Zhang C, Zhao S, et al. COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status. Infect Dis Poverty 2022;11:56.
  32. Luo D, Chen X, Du J, et al. Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: a systematic review and meta-analysis. Liver Int 2023;43:34-48.
  33. Li J, Ayada I, Wang Y, et al. Factors associated with COVID-19 vaccine response in transplant recipients: a systematic review and meta-analysis. Transplantation 2022;106:2068-75.